drugset / Trial / NCT01694186

Safety and Efficacy of an Injectable Fluocinolone Acetonide Intravitreal Insert

NCT01694186

Phase 3 Completed 129 enrolled EyePoint Pharmaceuticals, Inc.
RandomizedParallel-groupDouble-blindTreatment

Summary

A study to evaluate the safety and efficacy of an FAI insert for the management of subjects with non-infectious uveitis affecting the posterior segment of the eye.

Timeline

Start
2013-08-02
Primary completion
2018-03-26
Completion
2018-03-26

Drugs

EvaluationDrugModalityDoseRoute
Subject fluocinolone acetonide Small molecule 0.18 mg Intravitreal

Indications